Miltenyi Biotec Opens a New Office in South Korea
Miltenyi Biotec Opens a New Office in South Korea
AsiaNet 53530
BERGISCH GLADBACH, Germany, June 27, 2013 /PRN=KYODO JBN/--
Miltenyi Biotec, the world's leading cell innovation company, announced
today that it opened a new office in Seoul, Korea, enlarging the company's
Asia-Pacific presence to six locations in five countries.
"Miltenyi Biotec recognizes the potential of a Korean presence in achieving
strong, steady growth and expanding our global reach with a team of talented
people," said CEO Boris Stoffel. "Our new team has an exceptional ability to
partner with scientists and clinicians to generate exciting opportunities."
Daesuk Oh has been appointed General Manager of the new office in the
Gangnam district of Seoul. "Our location will be instrumental in developing
deeper relationships with a host of stem cell, immunology, translational
research, and clinical customers, as well as prospective research and clinical
institutions throughout South Korea. We're excited for the opportunity to bring
Miltenyi Biotec's solutions to scientists and clinicians who can truly benefit
from the quality and reliability the portfolio is known for," said Oh.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance
biomedical research. From research tools to GMP reagents, Miltenyi is making
the promise of cell therapy a reality. The company's integrated portfolio of
tools supports the translation of basic research into practical applications
for human health. Scientists and clinicians around the world use
Miltenyi-enabling technologies for effective sample preparation, cell
isolation, flow cytometry, cell culture, molecular analysis and preclinical
imaging. The MACS(R) brand has set standards in the industry and is trusted
across basic, translational, and clinical research settings. The company also
offers comprehensive technical support and training through its MACS(R)
Academy. Miltenyi Biotec has 1,400 employees in 22 countries.
Media Contact:
Prof. Dr. Uwe Heinlein
Phone: +49-2204-8306-6590
E-mail: press@miltenyibiotec.de
SOURCE: Miltenyi Biotec GmbH
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。